Breathe Well Live Well
|
GSK's First Biologic Treatment For Asthma – Nucala Holds Multi-Billion Dollar Potential
Seeking Alpha Nucala was recently approved by the USFDA and EMA for the treatment of patients with severe Asthma of eosinophilic phenotype. In the base case, Nucala should reach peak sales of $2b. If Nucala is approved in other indications (COPD, HES) too, it can … |
View full post on asthma – Google News
|
SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
PR Newswire (press release) RIDGEFIELD, Conn., Feb. 3, 2016 /PRNewswire/ — Boehringer Ingelheim Pharmaceuticals, Inc. today announced that SPIRIVA RESPIMAT is now available by prescription for the treatment of asthma in U.S. pharmacies. The U.S. Food and Drug … |
View full post on asthma – Google News
AAFP News |
AAFP NRN Study Sheds Light on Asthma Treatment in Black Adults
AAFP News Researchers found that among black adults with asthma who were treated with inhaled corticosteroids (ICS), adding a long-acting beta agonist (LABA) didn't improve time to asthma exacerbation compared with adding tiotropium (Spiriva). In addition … |
View full post on asthma – Google News
|
Asthma Treatment Market (2015 – 2021): Global Market Study And Analysis
Medgadget.com (blog) logo746 Asthma is a chronic inflammatory lung disease. Asthma affects personnel in all ages but mostly starts in childhood. Asthma creates inflammation in the inside walls of airways which makes airways very sensitive for the allergic reaction. Asthma … |
View full post on asthma – Google News
|
Surgical Treatment of Bronchial Asthma by Resection of the Laryngeal Nerve
Medscape Background: Management of asthma in chronically affected patients is a serious health problem. Our aim was to show that surgical treatment of chronic bronchial asthma by unilateral resection of the internal branch of the superior laryngeal nerve (ib … |
View full post on asthma – Google News
|
New treatment for severe asthma
Pharmacy Today, American Pharmacists Association, pharmacist.com In early November, FDA approved mepolizumab (Nucala—GlaxoSmithKline), a novel treatment for severe asthma. This new treatment is an interleukin-5 (IL-5) antagonist that works by inhibiting IL-5 signaling, with subsequent reduction in the production … |
View full post on asthma – Google News
 |
Related Articles |
Medical care and treatment of allergic rhinitis. A population-based cohort study based on routine healthcare utilization data.
Allergy. 2016 Jan 8;
Authors: Schmitt J, Stadler E, Küster D, Wüstenberg EG
Abstract
BACKGROUND: Health services research on medical care and treatment of allergic rhinitis (AR) is scarce.
OBJECTIVES: To investigate the prevalence, incidence, comorbidities, and treatment of AR in a realistic setting.
METHODS: A cohort of 1,811,094 German National Health Insurance beneficiaries in 2005 was followed until 2011. To avoid misclassification, the ICD-10-code for AR (J30) had to be documented at least twice to classify patients as having AR. Descriptive statistics and logistic regression models were used to describe the burden, comorbidities, and treatment of AR.
RESULTS: A total of 111,394 patients (6.2%) had prevalent AR in 2005/2006. In another 60,145 individuals (3.3%) AR was newly diagnosed in 2007 to 2011 (incident cases). Patients with prevalent AR were three times more likely to develop asthma compared to patients without AR (age and sex-adjusted risk ratio (RR) 3.04; 95% confidence interval (95%CI) 2.98 – 3.10). Newly diagnosed recurrent depressive disorder (RR 1.61; 95%CI 1.55 – 1.68), anxiety disorder (RR 1.52; 95%CI 1.48 – 1.56) and ADHD (RR 1.21; 95%CI 1.13 – 1.29) were also related to prevalent AR. Approximately 20% of children and 36% of adults with AR were exclusively treated by general practitioners. Allergy immunotherapy (AIT) was prescribed for 16.4% of AR patients. Subcutaneous immunotherapy was most frequently used (80% of AIT).
CONCLUSIONS: This study highlights the significant burden of AR. Despite the established benefits of AIT to treat AR and prevent asthma this study suggests significant undertreatment. Future research is necessary to develop and implement adequate measures to increase guideline adherence. This article is protected by copyright. All rights reserved.
PMID: 26749452 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Regulatory Focus |
Researchers Link FDA Actions to Decrease in LABA Use in Asthma Treatment
Regulatory Focus A recent study finds an association between regulatory actions by the US Food and Drug Administration (FDA) and the use of long-acting ?2-agonists (LABA) commonly used to treat asthma. The study, published in the Journal of Allergy and Clinical … Simple asthma screening test could improve care for children |
View full post on asthma – Google News
|
Asthma Treatment Market (2015 – 2021): Report Maps the Qualitative Impact of …
Medgadget.com (blog) logo137 Asthma is a chronic inflammatory lung disease. Asthma affects personnel in all ages but mostly starts in childhood. Asthma creates inflammation in the inside walls of airways which makes airways very sensitive for the allergic reaction. Asthma … |
View full post on asthma – Google News
|
Nebulizers, Inhalers and Respirators for Asthma Treatment Market (2015 – 2021 …
Medgadget.com (blog) logo85 Asthma is a chronic inflammatory lung disease which affects persons across all ages. It creates inflammation inside the walls of airways, causing airways to narrow, swell and produce extra mucous. It is caused due to genetic factors or … |
View full post on asthma – Google News